Literature DB >> 27189342

ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma.

Carlos L Morais1, Liana B Guedes1, Jessica Hicks1, Alexander S Baras1, Angelo M De Marzo2, Tamara L Lotan3.   

Abstract

High-grade prostatic intraepithelial neoplasia (HGPIN) is widely believed to represent a precursor to invasive prostatic adenocarcinoma. However, recent molecular studies have suggested that retrograde spread of invasive adenocarcinoma into pre-existing prostatic ducts can morphologically mimic HGPIN. Thus, previous molecular studies characterizing morphologically identified HGPIN occurring in radical prostatectomies or needle biopsies with concurrent invasive carcinoma may be partially confounded by intraductal spread of invasive tumor. To assess ERG and PTEN status in HGPIN foci likely to represent true precursor lesions in the prostate, we studied isolated HGPIN occurring without associated invasive adenocarcinoma in cystoprostatectomies performed at Johns Hopkins between 2009 and 2014. Of 344 cystoprostatectomies, 33% (115/344) contained invasive prostatic adenocarcinoma in the partially submitted prostate (10 blocks/case on average) and were excluded from the study. Of the remaining cases without sampled cancer, 32% (73/229) showed 133 separate foci of HGPIN and were immunostained for ERG and PTEN using genetically validated protocols. Of foci of HGPIN with evaluable staining, 7% (8/107) were positive for ERG. PTEN loss was not seen in any HGPIN lesion (0/88). Because these isolated HGPIN foci at cystoprostatectomy are unlikely to represent retrograde spread of invasive tumor, our study suggests that ERG rearrangement, but not PTEN loss, is present in a minority of potential neoplastic precursor lesions in the prostate.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ERG; Immunohistochemistry; PTEN; Prostatic carcinoma; Prostatic intraepithelial neoplasia (PIN); Radical cystoprostatectomy

Mesh:

Substances:

Year:  2016        PMID: 27189342      PMCID: PMC4981542          DOI: 10.1016/j.humpath.2016.04.017

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  49 in total

1.  Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma.

Authors:  Bisera Vukovic; Paul C Park; Jaudah Al-Maghrabi; Ben Beheshti; Joan Sweet; Andy Evans; John Trachtenberg; Jeremy Squire
Journal:  Oncogene       Date:  2003-04-03       Impact factor: 9.867

2.  ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia.

Authors:  Bo Han; Khalid Suleman; Lei Wang; Javed Siddiqui; Linda Sercia; Cristina Magi-Galluzzi; Nallasivam Palanisamy; Arul M Chinnaiyan; Ming Zhou; Rajal B Shah
Journal:  Am J Surg Pathol       Date:  2010-04       Impact factor: 6.394

3.  Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion.

Authors:  Carlise R Bethel; Dennis Faith; Xiang Li; Bin Guan; Jessica L Hicks; Fusheng Lan; Robert B Jenkins; Charles J Bieberich; Angelo M De Marzo
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

4.  TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.

Authors:  Kyung Park; James T Dalton; Ramesh Narayanan; Christopher E Barbieri; Michael L Hancock; David G Bostwick; Mitchell S Steiner; Mark A Rubin
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

Review 5.  Precursor lesions to prostatic adenocarcinoma.

Authors:  Jonathan I Epstein
Journal:  Virchows Arch       Date:  2008-12-02       Impact factor: 4.064

6.  ERG expression and prostatic adenocarcinoma.

Authors:  Montse Verdu; Isabel Trias; Ruth Roman; Natalia Rodon; Beatriz Garcia-Pelaez; Miquel Calvo; Arturo Dominguez; Josep M Banus; Xavier Puig
Journal:  Virchows Arch       Date:  2013-05-24       Impact factor: 4.064

7.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Authors:  Brett S Carver; Jennifer Tran; Anuradha Gopalan; Zhenbang Chen; Safa Shaikh; Arkaitz Carracedo; Andrea Alimonti; Caterina Nardella; Shohreh Varmeh; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

8.  Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.

Authors:  Bungo Furusato; Chun-Ling Gao; Lakshmi Ravindranath; Yongmei Chen; Jennifer Cullen; David G McLeod; Albert Dobi; Shiv Srivastava; Gyorgy Petrovics; Isabell A Sesterhenn
Journal:  Mod Pathol       Date:  2007-12-07       Impact factor: 7.842

9.  Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization.

Authors:  J Qian; D G Bostwick; S Takahashi; T J Borell; J F Herath; M M Lieber; R B Jenkins
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

10.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Authors:  Sven Perner; Juan-Miguel Mosquera; Francesca Demichelis; Matthias D Hofer; Pamela L Paris; Jeff Simko; Colin Collins; Tarek A Bismar; Arul M Chinnaiyan; Angelo M De Marzo; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

View more
  11 in total

1.  Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.

Authors:  Alba Torres; Mohammed Alshalalfa; Scott A Tomlins; Nicholas Erho; Ewan A Gibb; Jijumon Chelliserry; Lony Lim; Lucia L C Lam; Sheila F Faraj; Stephania M Bezerra; Elai Davicioni; Kasra Yousefi; Ashley E Ross; George J Netto; Edward M Schaeffer; Tamara L Lotan
Journal:  J Mol Diagn       Date:  2017-03-21       Impact factor: 5.568

2.  Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2.

Authors:  Ninghui Mao; Dong Gao; Wenhuo Hu; Sunyana Gadal; Haley Hieronymus; Shangqian Wang; Young Sun Lee; Patrick Sullivan; Zeda Zhang; Danielle Choi; Neal Rosen; Charles L Sawyers; Anuradha Gopalan; Yu Chen; Brett S Carver
Journal:  Cancer Res       Date:  2020-02-03       Impact factor: 12.701

Review 3.  Clinical implications of PTEN loss in prostate cancer.

Authors:  Tamara Jamaspishvili; David M Berman; Ashley E Ross; Howard I Scher; Angelo M De Marzo; Jeremy A Squire; Tamara L Lotan
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

Review 4.  ETS factors in prostate cancer.

Authors:  Cheng Qian; Dan Li; Yu Chen
Journal:  Cancer Lett       Date:  2022-01-14       Impact factor: 8.679

5.  Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.

Authors:  David J VanderWeele; Richard Finney; Kotoe Katayama; Marc Gillard; Gladell Paner; Seiya Imoto; Rui Yamaguchi; David Wheeler; Justin Lack; Maggie Cam; Andrea Pontier; Yen Thi Minh Nguyen; Kazuhiro Maejima; Aya Sasaki-Oku; Kaoru Nakano; Hiroko Tanaka; Donald Vander Griend; Michiaki Kubo; Mark J Ratain; Satoru Miyano; Hidewaki Nakagawa
Journal:  Eur Urol Focus       Date:  2018-02-15

Review 6.  Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities.

Authors:  Levent Trabzonlu; Ibrahim Kulac; Qizhi Zheng; Jessica L Hicks; Michael C Haffner; William G Nelson; Karen S Sfanos; Onur Ertunc; Tamara L Lotan; Christopher M Heaphy; Alan K Meeker; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  Cold Spring Harb Perspect Med       Date:  2019-04-01       Impact factor: 6.915

7.  Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer.

Authors:  Emmanuel S Antonarakis; Tamara L Lotan; Harsimar Kaur; Daniela C Salles; Sanjana Murali; Jessica L Hicks; Minh Nguyen; Colin C Pritchard; Angelo M De Marzo; Jerry S Lanchbury; Bruce J Trock; William B Isaacs; Kirsten M Timms
Journal:  Clin Cancer Res       Date:  2020-07-21       Impact factor: 12.531

8.  Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer.

Authors:  Eva Shrestha; Jonathan B Coulter; William Guzman; Busra Ozbek; Megan M Hess; Luke Mummert; Sarah E Ernst; Janielle P Maynard; Alan K Meeker; Christopher M Heaphy; Michael C Haffner; Angelo M De Marzo; Karen S Sfanos
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-10       Impact factor: 11.205

Review 9.  Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification.

Authors:  Kentaro Inamura
Journal:  Oncotarget       Date:  2018-02-16

Review 10.  Intraductal carcinoma of the prostate.

Authors:  Eszter Szentirmai; Giovanna Angela Giannico
Journal:  Pathologica       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.